A pioneering Merck cancer drug could soon become a go-to treatment option for advanced lung cancer after besting standard chemotherapy in a clinical trial.
The drug in question is the immunotherapy Keytruda (famous for being used to treat President Jimmy Carter’s melanoma). It was being tested in patients with a specific type of lung cancer called advanced non-small cell lung cancer (NSCLC) who also had high levels of a biological marker called PD-L1 (the treatment is most effective in patients whose tumors have that protein).
Read Full Article »